1. Home
  2. ENTX vs HNNA Comparison

ENTX vs HNNA Comparison

Compare ENTX & HNNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • HNNA
  • Stock Information
  • Founded
  • ENTX 2010
  • HNNA 1989
  • Country
  • ENTX Israel
  • HNNA United States
  • Employees
  • ENTX N/A
  • HNNA N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • HNNA Investment Managers
  • Sector
  • ENTX Health Care
  • HNNA Finance
  • Exchange
  • ENTX Nasdaq
  • HNNA Nasdaq
  • Market Cap
  • ENTX 69.6M
  • HNNA 82.4M
  • IPO Year
  • ENTX 2018
  • HNNA N/A
  • Fundamental
  • Price
  • ENTX $1.70
  • HNNA $9.96
  • Analyst Decision
  • ENTX Strong Buy
  • HNNA
  • Analyst Count
  • ENTX 1
  • HNNA 0
  • Target Price
  • ENTX $10.00
  • HNNA N/A
  • AVG Volume (30 Days)
  • ENTX 52.4K
  • HNNA 14.4K
  • Earning Date
  • ENTX 03-28-2025
  • HNNA 05-07-2025
  • Dividend Yield
  • ENTX N/A
  • HNNA 5.52%
  • EPS Growth
  • ENTX N/A
  • HNNA 75.66
  • EPS
  • ENTX N/A
  • HNNA 1.12
  • Revenue
  • ENTX $181,000.00
  • HNNA $33,210,000.00
  • Revenue This Year
  • ENTX N/A
  • HNNA N/A
  • Revenue Next Year
  • ENTX N/A
  • HNNA N/A
  • P/E Ratio
  • ENTX N/A
  • HNNA $9.24
  • Revenue Growth
  • ENTX N/A
  • HNNA 38.27
  • 52 Week Low
  • ENTX $1.41
  • HNNA $6.60
  • 52 Week High
  • ENTX $3.35
  • HNNA $13.88
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 33.66
  • HNNA 31.77
  • Support Level
  • ENTX $1.85
  • HNNA $10.35
  • Resistance Level
  • ENTX $2.02
  • HNNA $10.90
  • Average True Range (ATR)
  • ENTX 0.10
  • HNNA 0.39
  • MACD
  • ENTX -0.01
  • HNNA 0.02
  • Stochastic Oscillator
  • ENTX 11.57
  • HNNA 38.16

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About HNNA Hennessy Advisors Inc.

Hennessy Advisors Inc is an investment management company, engaged in the managing and marketing of open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, sectors, and specialty, balanced, and fixed income products. It also provides investment advisory services and shareholder services to the Hennessy Funds which include managing the composition of each fund's portfolio, including the purchase, retention, and disposition of portfolio securities as per the Fund's investment objectives, policies, and restrictions; conducting investment research, and monitoring compliance with each fund's investment restrictions and applicable laws and regulations.

Share on Social Networks: